1. Scrip
  2. >>Drug Pricing

What’s Next For ICER: An Interview With New President Sarah Emond

 
• By Jessica Merrill

The Institute for Clinical and Economic Review’s new president talked to Scrip in an interview about cell and gene therapy, obesity drugs and the new Medicare drug price negotiation program.

ICER President Sarah Emond
ICER president and CEO Sarah Emond • Source: ICER

The Institute for Clinical and Economic Review’s (ICER’s) new president and CEO Sarah Emond took over the role from the organization’s longtime leader and founder Steve Pearson on 1 January and in an interview at the J.P. Morgan Healthcare Conference in San Francisco, she discussed some of the pressing drug pricing issues on ICER’s radar for the year ahead.

Key Takeaways
  • Sarah Emond took over as president and CEO from the organization’s longtime leader and founder Steve Pearson on 1 January.

Emond has had a lengthy career at ICER, having worked for the organization for 14 years – most recently as...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Drug Pricing

Opportunities For AI In Pricing, Reimbursement Abound, But Use Remains Rare

 
• By Alaric DeArment

A July white paper from Lifescience Dynamics explores the potential ways AI could see usage in pricing, reimbursement and market access for biopharma companies.

Indegene Exec On DTP Distribution As A ‘Tactical Solution’, Feasibility Of MFN Model

 
• By Anju Ghangurde

Senior Indegene executive William Lobb talks about complexities of the direct-to-patient distribution model in the US and underlines that it isn’t a comprehensive healthcare fix. The feasibility of MFN pricing and why it may be “catastrophic” to the industry were some of the other topics discussed.

Lilly Begins Rebalancing US/Ex-US Drug Costs By Raising Prices In Europe

 
• By Mandy Jackson

Lilly said prices governments pay in developed countries, including those in Europe, need to increase to make US drug prices lower, rebalancing costs as CEO David Ricks recently advocated.

Lilly CEO Ricks Advocates Rebalancing Drug Pricing Between US And Europe

 
• By Mandy Jackson

As President Trump focuses on “most favored nation” pricing to bring down US drug costs, CEO David Ricks used Lilly’s Q2 earnings call to advocate for a slow approach to reducing the difference between US and EU drug prices.

More from Scrip

Stock Watch: Bloodbaths And Blood Letting At CSL And Bayer

 
• By Andy Smith

Financial announcements that report falling sales or profits may result in share price weakness, while big restructurings, or their extended continuation, can elicit protest votes from shareholders.

GSK India Oncology Second Innings: Can Jemperli, Zejula Set The Pace?

 
• By Anju Ghangurde

GSK recommits to oncology in India with the debut of Jemperli and Zejula, backed by a tiered pricing approach, patient support program and efforts to address unmet needs in the biomarker ecosystem. Can it widen treatment access materially?

US FDA Suspends Valneva’s Ixchiq Based On Four New Serious AE Reports

 
• By Sue Sutter

After an Aug. 6 safety labeling change, the FDA became aware of “more compelling evidence” that the risk for serious chikungunya-like illness is not limited to older adults, CBER Director Prasad said.